Detalhe da pesquisa
1.
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.
J Thorac Oncol
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38460751
2.
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Cancer Cell
; 41(6): 1061-1072.e4, 2023 06 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207654